Patients with platinum-resistant ovarian , fallopian tube or primary peritoneal cancer were randomised 2 : 1 to receive 8-week cycles of weekly paclitaxel ( wPxl ; 80 mg/m ( 2 ) / week 6 with 2-week break ) plus saracatinib ( S ; 175 mg o.d. ) or placebo ( P ) continuously , starting 1 week before wPxl , until disease progression .